GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Beyond Air Inc (NAS:XAIR) » Definitions » Beneish M-Score

XAIR (Beyond Air) Beneish M-Score : -0.24 (As of Mar. 14, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Beyond Air Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -0.24 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Beyond Air's Beneish M-Score or its related term are showing as below:

XAIR' s Beneish M-Score Range Over the Past 10 Years
Min: -6.09   Med: -0.24   Max: 53.83
Current: -0.24

During the past 10 years, the highest Beneish M-Score of Beyond Air was 53.83. The lowest was -6.09. And the median was -0.24.


Beyond Air Beneish M-Score Historical Data

The historical data trend for Beyond Air's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beyond Air Beneish M-Score Chart

Beyond Air Annual Data
Trend Jun15 Jun16 Dec17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.35 1.62 - - -

Beyond Air Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 30.24 3.39 -0.24

Competitive Comparison of Beyond Air's Beneish M-Score

For the Medical Devices subindustry, Beyond Air's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beyond Air's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Beyond Air's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Beyond Air's Beneish M-Score falls into.



Beyond Air Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Beyond Air for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.2727+0.528 * 2.2531+0.404 * 1.2337+0.892 * 4.3875+0.115 * 0.7653
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.1608+4.679 * -0.254803-0.327 * 0.3795
=-0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Total Receivables was $0.64 Mil.
Revenue was 1.072 + 0.798 + 0.683 + 0.47 = $3.02 Mil.
Gross Profit was -0.215 + -1.084 + -0.332 + -0.513 = $-2.14 Mil.
Total Current Assets was $19.34 Mil.
Total Assets was $34.14 Mil.
Property, Plant and Equipment(Net PPE) was $13.43 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.37 Mil.
Selling, General, & Admin. Expense(SGA) was $28.56 Mil.
Total Current Liabilities was $5.43 Mil.
Long-Term Debt & Capital Lease Obligation was $1.57 Mil.
Net Income was -13.032 + -13.358 + -12.201 + -13.707 = $-52.30 Mil.
Non Operating Income was -1.833 + -0.27 + 1.49 + -0.999 = $-1.61 Mil.
Cash Flow from Operations was -7.733 + -13.348 + -10.18 + -10.725 = $-41.99 Mil.
Total Receivables was $0.53 Mil.
Revenue was 0.391 + 0.239 + 0.059 + 0 = $0.69 Mil.
Gross Profit was -0.356 + -0.193 + -0.244 + -0.308 = $-1.10 Mil.
Total Current Assets was $39.44 Mil.
Total Assets was $51.91 Mil.
Property, Plant and Equipment(Net PPE) was $10.78 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.96 Mil.
Selling, General, & Admin. Expense(SGA) was $40.47 Mil.
Total Current Liabilities was $11.64 Mil.
Long-Term Debt & Capital Lease Obligation was $16.39 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.639 / 3.023) / (0.534 / 0.689)
=0.211379 / 0.775036
=0.2727

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(-1.101 / 0.689) / (-2.144 / 3.023)
=-1.597968 / -0.709229
=2.2531

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (19.344 + 13.427) / 34.144) / (1 - (39.439 + 10.78) / 51.911)
=0.040212 / 0.032594
=1.2337

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=3.023 / 0.689
=4.3875

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.955 / (1.955 + 10.78)) / (3.369 / (3.369 + 13.427))
=0.153514 / 0.200583
=0.7653

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(28.556 / 3.023) / (40.465 / 0.689)
=9.446245 / 58.730044
=0.1608

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1.567 + 5.43) / 34.144) / ((16.392 + 11.641) / 51.911)
=0.204926 / 0.54002
=0.3795

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-52.298 - -1.612 - -41.986) / 34.144
=-0.254803

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Beyond Air has a M-score of -0.24 signals that the company is likely to be a manipulator.


Beyond Air Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Beyond Air's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Beyond Air Business Description

Traded in Other Exchanges
Address
900 Stewart Avenue, Suite 301, Garden City, New York, NY, USA, 11530
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
Executives
Robert Carey director HORIZON PHARMA, INC., 520 LAKE COOK ROAD, SUITE 520, DEERFIELD IL 60062
Steven A. Lisi director 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635
Erick Lucera director 138 THISTLE ROAD, NORTH ANDOVER MA 08145
Amir Avniel director, officer: President & CEO 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635
Jeff Lynn Myers officer: Chief Medical Officer C/O BEYOND AIR, INC., 900 STEWART AVENUE, SUITE 301, GARDEN CITY NY 11530
Michael A. Gaul officer: Chief Operating Officer 425 MARTINGALE ROAD, SUITE 1000, SCHAUMBURG IL 60173-2213
William P Forbes director C/O SALIX PHARMACEUTICALS, LTD., 8510 COLONNADE CENTER DRIVE, RALEIGH NC 27615
Yoori Lee director C/O AIT THERAPEUTICS, INC., 500 MAMARONECK AVENUE, HARRISON NY 10528
Ron Bentsur director 750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Douglas Quinton Larson officer: Chief Financial Officer BEYOND AIR, INC., 900 STEWART AVENUE, SUITE 301, GARDEN CITY NY 11530
Douglas Beck officer: Chief Financial Officer C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Ari Raved director 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
David Grossman director 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635
Haim Aviv officer: Chief Financial Officer 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635